Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Corporate Update (April 2020)
14 slides from Sutro Biopharma's corporate update, Apr 27, 2020
Slide 1: Sutro Biopharma Analyst and Investor Conference Call
NASDAQ: STRO Bill Newell, CEO Sutro Biopharma Analyst and Investor Conference Call April 27, 2020 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: STRO-002-GM1 First in Human Phase 1 Study of STRO-002 in Ovarian Cancer
CONFIDENTIAL STRO-002-GM1, a First in Human, Phase 1 study of STRO-002, an anti-Folate Receptor-alpha (FRα) Antibody Drug Conjugate, in Patients with Advanced Platinum Resistant/Refractory Epithelial Ovarian Cancer, including Fallopian Tube or Primary Peritoneal Cancers R. Wendel Naumann, Denise Uya
Slide 4: STRO-002-GM1 Phase 1 Study Was Initiated in March 2019
STRO-002-GM1, Phase 1 Study was Initiated in March 2019 Key Inclusion: Advanced platinum-resistant/refractory disease; patients are not selected for FRα expression (all comers) Key Exclusion: Prior FolRα targeting ADC, low grade ovarian carcinoma, clinically significant pre-existing ocular disorders
Slide 5: Patient Demographics and Disease Characteristics
Patient Demographics and Disease Characteristics CONFIDENTIAL Reported April 27, 2020 (Data as of April 20, 2020) Characteristic Total N = 30 (%) Age, median (range), years 60.5 (47-76) Tumor type EOC 25 (83) Fallopian tube 3 (10) Primary peritoneal 2 (7) ECOG PS 0 17 (57) 1 13 (43) Median time from
Slide 6: 62% of Patients Treated at ≥2.9 mg/kg Have ≥50% Reduction or Normalization of CA-125
62% (13/21) of Patients Treated at ≥ 2.9 mg/kg with Post-baseline Assessments Have ≥ 50% Reduction or Normalization of CA-125 CONFIDENTIAL 50% reduction X axis- post C1D1 assessments Y axis- change from C1D1 CA-125 Data as of 20 Apr 2020 CA-125 Responses 6 confirmed CA-125 responses 1 sustained CA-1
Slide 7: 35% of Evaluable Patients at ≥2.9 mg/kg Remained on Study >24 Weeks
35% (7/20) Patients Evaluable for Progression at ≥ 2.9 mg/kg Remained on Study > 24 weeks 2.9 mg/kg 4.3 mg/kg 6.0 mg/kg Duration calculated as time to PD from 1st dose or according to doses received (2 doses = 3 weeks, 3 doses= 6 weeks, etc.) 5.2 mg/kg 5.6 mg/kg 6.4 mg/kg On study PD leading to disc
Slide 8: 75% of Patients at ≥2.9 mg/kg Have Stable Disease or Partial Response
75% (15/20*) of Patients Treated at ≥ 2.9 mg/kg Have Initial Post-Baseline Scans Showing Stable Disease or Partial Response 2.9 mg/kg 4.3 mg/kg 6.0 mg/kg 5.2 mg/kg 5.6 mg/kg 6.4 mg/kg On study Confirmed PR Unconfirmed SD Confirmed SD Unconfirmed PR PD (RECIST or UCP) Data as of 20 Apr 2020 CONFIDENT
Slide 9: All Patients with CA-125 Response Remain on Study and Achieved Tumor Control
All Patients with CA-125 ≥ 50% Reduction or Normalization Remain on Study Treatment and 12/12 (100%) Achieved Tumor Control 2.9 mg/kg 4.3 mg/kg 6.0 mg/kg 5.2 mg/kg 5.6 mg/kg 6.4 mg/kg On study Confirmed PR Unconfirmed SD Confirmed SD Unconfirmed PR PD (RECIST or UCP) Data as of 20 Apr 2020 Confirmed
Slide 10: Treatment Emergent AEs in ≥20% of Patients
Treatment Emergent AEs in ≥ 20% of Patients (without causality attribution) Data as of 20 Apr 2020 Treatment Emergent Adverse Events (TEAE) TEAE >20% Grade 1 Grade 2 Grade 3 Grade 4* N= 29 (%) Fatigue 7 (24) 10 (35) 2 (7) 19 (66) Nausea 13 (45) 4 (14) 17 (59) Neutropenia/ Neutrophil count decreased
Slide 11: STRO-002 Emerging Safety Profile and Clinical Benefit Are Encouraging
STRO-002 Emerging Safety Profile, Evidence of Anti-tumor Activity and Clinical Benefit are Encouraging – AACR April 27, 2020 CONFIDENTIAL 62% (13/21) Patients at 2.9 mg/kg or higher with post baseline assessments have had a ≥ 50% reduction in CA-125 levels or normalization of CA-125 75% (15/20) Pati
Slide 12: Summary - Well Tolerated, Encouraging Clinical Benefit, Expansion Cohorts Planned for 2H20
Summary - Well Tolerated, Encouraging Clinical Benefit Expansion Cohorts Planned for 2H20 CONFIDENTIAL STRO-002 was generally well tolerated and mostly associated with mild events 5/30= 17% have not had post-treatment scan for initial RECIST assessment 89% of all AEs reported are grade 1 or 2 Prophy
Slide 13: Thank You to the Patients, Families and Study Site Investigators
Thank You to the Patients, their Families and our Participating Study Site Investigators and Staff CONFIDENTIAL Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC Medical College of Wisconsin, Milwaukee, WI University of Chicago, Chicago, IL Comprehensive Cancer Centers of Nevada, Las
Slide 14: Sutro Biopharma Analyst and Investor Conference Call
NASDAQ: STRO Bill Newell, CEO Sutro Biopharma Analyst and Investor Conference Call April 27, 2020